Abstract:The nucleotide-binding, oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) inflammasome is a multiprotein complex that combines sensing, regulation, and effector functions to regulate inflammation in health and disease. NLRP3 is activated by a diverse range of inflammation-instigating signals known as pathogen associated molecular patterns and danger associated molecular patterns. Upon activation, NLRP3 oligomerizes and recruits partner proteins to form a supramolecular platform to process the maturation and release of interleukin (IL)-1 β , IL-18, and gasdermin D, major mediators of inflammation and inflammatory cell death termed pyroptosis. The NLRP3 inflammasome has been implicated in the pathogenesis of a wide range of disease conditions, including chronic inflammatory disease that are associated with lifestyle and dietary changes, aging, and environmental exposures, and have become the leading cause of death worldwide. Pharmacological targeting of NLRP3 and signaling demonstrated promising efficacy in ameliorating a list of disease conditions in animal models. These findings underscore the potential and importance of NLRP3 as a druggable target for treating a range of diseases. In this review, recent progress in understanding the structure and mechanism of action of the NLRP3 inflammasome is discussed with focus on pharmacological inhibition of NLRP3 by small molecule inhibitors. New structural and mechanistic insights into NLRP3 activation and inhibitor-NLRP3 interactions would aid in the rational design and pharmacological evaluation of NLRP3 inhibitors for treatment of human disease. Significance Statement The NLRP3 inflammasome plays central role in innate immune sensing and control of inflammation. Pharmacological inhibition of NLRP3 demonstrated promising efficacy in a range of diseases in animal models. Recent elucidation of the structure and inhibitor binding of NLRP3 generated new insights into its mode of action and inhibitor-NLRP3 interaction at molecular levels, providing new framework for developing small chemical inhibitors of NLRP3 with improved efficacy and specificity against chronic disease that has become major health concerns worldwide.

Modulating NLRP3 splicing with antisense oligonucleotides to control pathological inflammation

Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice

Targeted blocking of gene splicing can dysregulate intron-embedded microRNAs

Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression

RNA Binding Proteins that Mediate LPS-induced Alternative Splicing of the MyD88 Innate Immune Regulator

Targeting of NLRP3 Inflammasome with Gene Editing for the Amelioration of Inflammatory Diseases

Uniting Alternative Splicing and Arthritis

Pharmacological Inhibitors of the NLRP3 Inflammasome

Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction

A framework for individualized splice-switching oligonucleotide therapy

Modulation of prion protein expression through cryptic splice site manipulation

Inhibition of NLRP3 inflammasome activation by cell-permeable stapled peptides

Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases

One-Size-Fits-Many: Antisense oligonucleotides for rescuing splicing mutations in hotspot exons

CWC22-Mediated Alternative Splicing of Spp1 Regulates Nociception in Inflammatory Pain

Targeting NLRP3 Inflammasomes: A Trojan Horse Strategy for Intervention in Neurological Disorders

Spirodalesol Analog 8A Inhibits NLRP3 Inflammasome Activation and Attenuates Inflammatory Disease by Directly Targeting Adaptor Protein ASC.

OLIGONUCLEOTIDES TARGETING THE SPLICE ACCEPTOR SITE DOWNSTREAM OF A MICROEXON AS AN INNOVATIVE THERAPY FOR AUTISM

USP19 Suppresses Inflammation and Promotes M2-like Macrophage Polarization by Manipulating NLRP3 Function Via Autophagy

Splicing Modulation via Antisense Oligonucleotides in Recessive Dystrophic Epidermolysis Bullosa

Inhibition of IRE1α RNase activity reduces NLRP3 inflammasome assembly and processing of pro-IL1β